Completed PHASE2 INTERVENTIONAL 2-arm NCT00531934

A Study of Management of Tarceva - Induced Rash in Patients With Non-Small Cell Lung Cancer.

A Randomized, Open Label Study to Evaluate the Effect of Doxycycline on Tarceva-induced Skin Rash in Patients With Non-small Cell Lung Cancer After Failure of First Line Chemotherapy

Sponsor: Hoffmann-La Roche

Conditions Non-Small Cell Lung Cancer

Interventions Doxycline erlotinib [Tarceva]

Updated 6 times since 2017 Last updated: Feb 5, 2015 Started: Oct 31, 2007 Primary completion: Aug 31, 2010 Completion: Aug 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Non-Small Cell Lung Cancer, this trial is completed. The trial is conducted by Hoffmann-La Roche and has accumulated 6 data snapshots since 2007. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Oct 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hoffmann-La Roche

Data source: Hoffmann-La Roche

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Antibes, France , Bordeaux, France , Brest, France , Caen, France , Chalon-sur-Saône, France , Chartres, France , Draguignan, France , Gap, France , Gleizé, France , Limoges, France and 11 more locations